Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Trial Profile

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Henlius Biotech
  • Most Recent Events

    • 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top